PLAU Antikörper

Produktnummer ABIN7101951

Produktdetails anti-PLAU Antikörper

Target: PLAU (Plasminogen Activator, Urokinase (PLAU))

Reaktivität: Human

Wirt: Ziege

Klonalität: Polyklonal

Konjugat: Dieser PLAU Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA), Immunohistochemistry (Frozen Sections) (IHC (fro)), Dot Blot (DB)

Spezifität: The antibody binds to human HMW-scuPA (54 kDa), HMW-tsuPA (52 kDa) and LMW-scuPA (33 kDa) with high apparent affinity (Kd= 0.1 nM) completely inhibiting the ability of urokinase to activate plasminogen. Urokinase reaction with synthetic substrate S2444 is also inhibited. The antibody is highly specific for urokinase, no crossreactions were found with other serine proteases (tissue plasminogen activator, plasmin, trypsin, chymotrypsin, elastase, thrombin). Human whole plasma or plasma proteins do not interfere with its binding to urokinase.

Kreuzreaktivität (Details): Species reactivity (tested):Human.

Aufreinigung: Affinity Chromatogryphy: The affinity purified antibody is obtained by binding to immobilized native Human Urokinase (antigen used for immunization), followed by elution with acidic buffer, neutralization, dialysis, dispensing and lyophilization.

Immunogen: Extensively purified native HMW-tcuPA and LMW-scuPA (mixture 50/50), isolated from Human urine. Pooled antisera are passed over DEAE-cellulose to produce IgG-enriched fraction, which is further subjected to absorption with immobilized total human serum proteins in order to remove non-specific antibodies.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Rekonstitution: Restore with 1 mL distilled water and add preservative if preferred.

Buffer: PBS with Mannitol

Handhabung: Avoid repeated freezing and thawing.

Details zu PLAU

Target: PLAU (Plasminogen Activator, Urokinase (PLAU))

Andere Bezeichnung: uPA / PLAU (PLAU Produkte)

Synonyme: PLAU antikoerper, u-PA antikoerper, ATF antikoerper, BDPLT5 antikoerper, QPD antikoerper, UPA antikoerper, URK antikoerper, uPA antikoerper, UPAM antikoerper, plasminogen activator, urokinase antikoerper, urokinase-type plasminogen activator antikoerper, PLAU antikoerper, CpipJ_CPIJ002131 antikoerper, CpipJ_CPIJ006543 antikoerper, CpipJ_CPIJ013396 antikoerper, CpipJ_CPIJ013623 antikoerper, Plau antikoerper

Hintergrund: This gene encodes a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation. A specific polymorphism in this gene may be associated with late-onset Alzheimer's disease and also with decreased affinity for fibrin-binding. This protein converts plasminogen to plasmin by specific cleavage of an Arg-Val bond in plasminogen. Plasmin in turn cleaves this protein at a Lys-Ile bond to form a two-chain derivative in which a single disulfide bond connects the amino-terminal A-chain to the catalytically active, carboxy-terminal B-chain. This two-chain derivative is also called HMW-uPA (high molecular weight uPA). HMW-uPA can be further processed into LMW-uPA (low molecular weight uPA) by cleavage of chain A into a short chain A (A1) and an amino-terminal fragment. LMW-uPA is proteolytically active but does not bind to the uPA receptor. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq]Synonyms: U-plasminogen activator, Urokinase, Urokinase-type plasminogen activator, Urokinase-type plasminogen activator chain B, Urokinase-type plasminogen activator long chain A, Urokinase-type plasminogen activator short chain A

Gen-ID: 5328

NCBI Accession: NP_001138503

Pathways: Cellular Response to Molecule of Bacterial Origin, Carbohydrate Homeostasis, Autophagie, Smooth Muscle Cell Migration